NSEGeneral Updates4 Jul 2026 · 4 Jul 2026, 10:34 am
General Updates
Supriya Lifescience Limited · SUPRIYA
✦ AI Summary▼ NegativeRegulatory
Supriya Lifescience Limited has informed the Exchange about General Updates regarding judicial proceedings involving a Personnel of the Company. The investigation has been initiated against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern8/10
Regulatory Risk9/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment4/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Supriya Lifescience Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
SUPRIYA_04072026103417_SEIntimation040726.pdf
View document text
July 04, 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block,
Dalal Street, Bandra-Kurla Complex
Mumbai- 400 001 Bandra (E), Mumbai - 400 051
Scrip Code: 543434 NSE Symbol: SUPRIYA
Dear Sir/Madam,
Subject: Intimation regarding judicial proceedings involving a Personnel of the Company
Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, and other applicable laws, and in accordance with the Regulation 30 read with Para
B of Part A of Schedule III of the Listing Regulations and SEBI circular dated July 13, 2023 SEBI Listing
Regulations, this is to inform you that the investigation has been initiated yesterday against Mr.
Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special
Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody
has been granted by CMM court till July 17, 2026.
The Company remains committed to maintaining the highest standards of corporate governance and
regulatory compliance. The Company is closely monitoring the developments in the case and any further
material developments in the matter shall be disclosed to the stock exchanges in accordance with
applicable laws and regulations.
The details of the case as required under Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated
13th July 2023 are enclosed herewith as Annexure A to the disclosure.
Kindly take the above information on record.
Thanking you.
Yours faithfully,
For Supriya Lifescience Limited
Prachi Sathe
Company Secretary & Compliance Officer
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE
Annexure - A
Sr. Particulars Details
1. Name Sreekant Sreedharan
2. Designation General Manager, Sales &
Marketing
3. Name of the Authority/ Competent Court Special Investigation and
Intelligence branch of Customs
Department
4. Date of occurrence of the event July 3, 2026
5. Details of the violation(s)/contravention(s) committed or Proceedings have been initiated
alleged to be committed against the personnel of the
Company yesterday under the
Narcotic Drugs and
Psychotropic Substances
(NDPS) Act, 1985 for a
procedural lapse for a single
export transaction of identified
product for which the said
officer is under Judicial
detention.
6. Impact on financial, operation or other activities of the Based on information currently
listed entity, quantifiable in monetary terms to the available with the Company, the
extent possible. proceedings are not expected to
have any material impact on the
operations, financial position, or
governance of the Company
7. Action(s) taken by listed company with respect to the The Company is evaluating the
communication implications of the proceedings
and is obtaining appropriate
legal advice.
8. Any other relevant information The matter is before the
competent court, and the
Company will take an
appropriate action after
examining all applicable legal
provisions and implications."
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE